Therapeutic Asset Ratings
120 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Allostim®
Metastatic Colorectal Cancer
Mirror Biologics, Inc.
P2/3
B
(58)
Panobinostat
Metastatic Colorectal Cancer
Oslo University Hospital
P2
B
(57)
Sevacizumab
Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
P3
B
(56)
Telisotuzumab Adizutecan
Metastatic Colorectal Cancer
AbbVie
P3
B
(56)
Atezolizumab
Metastatic Colorectal Cancer
National Cancer Institute (NCI)
P2
B
(56)
Avelumab
Metastatic Colorectal Cancer
Mirror Biologics, Inc.
P3
CCC
(55)
S-1
Metastatic Colorectal Cancer
Tao Zhang
P2
CCC
(55)
Everolimus
Metastatic Colorectal Cancer
Oslo University Hospital
P2
CCC
(54)
Envafolimab
Metastatic Colorectal Cancer
Sun Yat-sen University
P2/3
CCC
(54)
Bevacizumab-Awwb
Metastatic Colorectal Cancer
Amgen
P3
CCC
(52)
Nitazoxanide
Metastatic Colorectal Cancer
Tanta University
P3
CCC
(52)
Precemtabart Tocentecan
Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc.
P3
CCC
(52)
Pucotenlimab
Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
P3
CCC
(52)
Sulfasalazine
Metastatic Colorectal Cancer
Tanta University
P3
CCC
(52)
Bafisontamab
Metastatic Colorectal Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd.
P2
CCC
(52)
Fludarabine
Metastatic Colorectal Cancer
City of Hope Medical Center
P2
CCC
(52)
Tislelizumab
Metastatic Colorectal Cancer
Sir Run Run Shaw Hospital
P2
CCC
(52)
TRASTUZUMAB
Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
P2
CCC
(52)
Ziv-Aflibercept
Metastatic Colorectal Cancer
National Cancer Institute (NCI)
P2
CCC
(52)
Ctx-009
Metastatic Colorectal Cancer
Compass Therapeutics
P2
CCC
(51)
Dasatinib
Metastatic Colorectal Cancer
Oslo University Hospital
P2
CCC
(51)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Metastatic Colorectal Cancer
Fudan University
P2
CCC
(51)
Tiragolumab
Metastatic Colorectal Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
Acetylsalicylic Acid
Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
P2/3
CCC
(50)
Lapatinib
Metastatic Colorectal Cancer
Fudan University
P2
CCC
(49)
Showing 26 to 50 of 120 assets
Previous
Page 2 of 5
Next
